OncoMatch/Clinical Trials/NCT05270200
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Is NCT05270200 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Azacitidine and Chidamide for leukemia, myeloid, acute.
Treatment: Azacitidine · Chidamide — The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Blood counts
neutrophil count greater than 1.5×10/L without G-CSF; platelet count greater than 80×10/L without platelet transfusion
Kidney function
serum creatinine clearance rate is greater than 30ml/min
Liver function
bilirubin, ALT and AST all less than 3 times the upper limit of normal
bilirubin, ALT and AST were all less than 3 times the upper limit of normal; neutrophil count greater than 1.5×10/L and without G-CSF treatment; platelet count greater than 80×10/L and without platelet transfusion; serum creatinine clearance rate is greater than 30ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify